抗体药物的发展现状及展望
Development Status and Prospect of Antibody Drugs
DOI: 10.12677/PI.2013.23008, PDF, HTML, XML, 下载: 3,862  浏览: 14,166  国家自然科学基金支持
作者: 刘要南, 王文飞：东北农业大学生命科学学院，哈尔滨
关键词: 抗体；药物；发展趋势； Antibody; Drugs; Growing Trend
摘要:

过了多年的发展，抗体药物已经从原来的多克隆外源抗体过渡到单克隆抗体、人源化抗体、小分子抗体以及目前的全人抗体药物。在临床使用中，抗原靶标及作用机制特点决定了抗抗体药物在临床使用中的安全性和疗效。目前，市场上抗体药物的发展速度要显著高于化学药物，本文就抗体药物发展的历史、现状、市场及未来展望作了简要综述。

Abstract: After years of development, antibody drugs have made the transition from the polyclonal exogenous antibody to the monoclonal antibodies, humanized antibodies, small molecule antibodies and the fully human antibodies. The safety and effectiveness of therapeutic antibody drugs in clinical practice depend on the nature of the target antigens and the mechanisms. At present, the growth ratio of the antibody drugs is higher than that of chemical compounds in the market. This review provides a brief summary of the history, current state, market and the trend of antibody dugs.

文章引用：刘要南, 王文飞. 抗体药物的发展现状及展望[J]. 药物资讯, 2013, 2(3): 37-41. http://dx.doi.org/10.12677/PI.2013.23008

参考文献

[1] M. Lhira, T. Yoshikawa, Y. Enomodo, et al. Rapid diagnosis of human herpes virus 6 infection by a novel DNA amplification method, loop-mediated isothermal amplification. Journal of Cli- nical Microbi-ology, 2004, 42(1): 140-145.
[2] JM沃克等编, 谭天伟等译. 分子生物学与生物技术[M]. 北京: 化学工业出版社, 2003.
[3] 卢圣栋. 现代分子生物学实验技术[M]. 北京: 中国协和医科大学出版社, 1999.
[4] D. Hughes. Therapeutic antibodies make a comeback. Drug Dis- covery Today, 1998, 3(10): 439-442.
[5] D. Mclaughlin. Ri-tuximab: Perspective on single agent experi- ence, and future direc-tions in combination trials.•Critical Re- views in Oncol-ogy/Hematology, 2001, 40(10): 3-16.
[6] J. M. Reichert, C. K. Rosensweug, L. B. Faden, et al. Monoelonal antibody success in the clinic. Nature Biotechnology, 2005, 23(9): 1073.
[7] S Muyldermans, T. N. Baral, V. C. Retamozzo, et al. Camelid immunoglobulins and nano-body technology. Veterinary Immu- nology and Immunopathology, 2009, 128(1-3): 178-183.
[8] J. Wesolowski, V. Alzogaray, J. Reyelt, et al. Single domain antibodies: Promising experimental and therapeu-tic tools in in- fection and immunity. Medical Microbiology and Im-munology, 2009, 198(3): 157-174.
[9] J. A. Kolkman, D. A. Law. Nanobodies—From llamas to thera- peutic proteins. Drug Discovery Today: Technologies, 2010, 7(2): e139-e146.
[10] B. Stijlemans, G. Caljon, S. K. A. Natesan, et al. High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis. PLOS Pathogens, 2011, 7(6): e1002072.
[11] I. Hmila, D. Saerens, R. Ben Abderrazek, et al. A bispecific nanobody to provide full protection against lethal scorpion en- venoming. The FASEB Journal, 2010, 24(9): 3479-3489.
[12] R. Klooster, M. R. Eman, Q. Le Duc, et al. Selection and char- acterization of KDEL-specific VHH antibody fragments and their application in the study of ER resident protein expression. Journal of Immunological Methods, 2009, 342(1-2): 1-12.
[13] 王志明, 杨丽霞, 贾寅星, 贺丞基. 基于新兴技术的单克隆抗体药物的研究进展[J]. 中国新药杂志, 2012, 21(18): 2149- 2154.
[14] M. Goozner. FDA increases focus on postmarketing studies. Journal of the National Cancer Institute, 2010, 102(17): 1302- 1304.
[15] R. Bargou, E. Leo, G. Zugmaier, et al. Tumor regression in can- cer patients by very low doses of a T cell-engaging antibody. Science, 2008, 321(5891): 974-977.
[16] D. M. Goldenberg, E. A. Rossi, R. M. Sharkey, et al. Multifunc- tional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. Journal of Nuclear Medicine, 2008, 49(1): 158-163.
[17] P. Chames, D. Baty. Bispecific antibodies for cancer therapy: The light at the end of the tunnel? Mabs, 2009, 1(6): 539-547.
[18] M. Sebastian, P. Kiewe, W. Schuette, et al. Treatment of malig- nant pleural effusion with the trifunctional antibody catumaxo- mab (Removab) (anti-EpCAM × Anti-CD3): Results of a phase 1/2 study. Journal of Immunotherapy, 2009, 32(2): 195-202.
[19] A. Natsume, M. In, H. Takamura, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Research, 2008, 68(10): 3863-3872.
[20] T. Robak. GA-101, a third-generation, humanized and glycol- engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Current Opinion in Investigational Drugs, 2009, 10(6): 588-596.
[21] 周晓冰, 李波. 食蟹猴静脉注射抗CD20 功能人源化单克隆抗体(SM09)重复给药毒性研究[J]. 中国新药杂志, 2012, 21(6): 616-622.
[22] F. Van Bockstaele, J. B. Holz and H. Revets. The de-velopment of nanobodies for therapeutic applications. Current Opinion in Investigational Drugs, 2009, 10(11): 1212-1224.
[23] H. Ulrichts, K. Silence, A. Schoolmeester, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood, 2011, 118(3): 757-765.
[24] 《生物谷》《生物医药产业》《新药研发动态》国际新药研发动态, 2013.
[25] 美国食品药品管理局(FDA)批准的治疗性抗体药物[URL]. http://oneyao.net/article /2011/0411/25585.html
[26] 魏赟. 中国抗体药后来居上[N]. 医药经济报, 2010-7-28(003).